The scope of external quality assessment (EQA) 1 in laboratory medicine has evolved considerably (1 ) . With the increasing worldwide interest in the use of common reference intervals and/or medicaldecision limits, modern EQA schemes need to be better at assessing the standardization status of commercial in vitro diagnostic tests. This need has led to new challenges in the design of EQA surveys.
We report the outcomes of a Norwegian pilot study that investigated the use of commutable, fresh-frozen single donations to assess the current standardization status as part of an initiative toward producing common reference intervals (2 ) . The study covered measurements of calcium, magnesium, albumin, and total protein in serum from 20 singledonation blood samples obtained from Solomon Park Research Laboratories. Serum was generated according to CLSI protocol C37-A, with 2 U human thrombin (SigmaAldrich) added per milliliter of plasma to facilitate clotting (3 ); filtration was not used. Aliquots of these samples were sent to laboratories that used the same test systems (instrument, reagent, and calibrator from the same source). Five peer groups (n Ն 6 laboratories each; N ϭ 47) were considered: Abbott Diagnostics ARCHITECT, Ortho Clinical Diagnostics VITROS, Roche Diagnostics COBAS, Roche Diagnostics MODULAR, and Siemens Healthcare Diagnostics ADVIA. Target values were calculated for each peer group as the mean of the means of duplicate measurements (2 different runs); grossly outlying replicates were detected visually and omitted from the calculations (calcium, 6 replicates; magnesium, 1; albumin, 5; total protein, 2). The peer groups were checked for outliers with the Grubbs test. Finally, the overall values of target analytes (Mean overall ) were calculated as the mean of the peer group means. Note that the Abbott ARCHITECT peer group for magnesium was excluded from the Mean overall (outlier in Grubbs test). The concentration ranges for Mean overall covered by the panels were as follows: calcium, 8.36 -9.37 mg/dL (2.09 -2.34 mmol/L); magnesium, 1.71-2.20 mg/dL (0.70 -0.91 mmol/L); albumin, 3.56 -4.58 g/dL; total protein, 5.34 -7.13 g/dL. System comparability was assessed by correlation, linear regression, and differences of peer group means from the Mean overall . The rationale for using this approach was the assumption that globally operating manufacturers have standardized their systems by means of a trueness-based reference measurement system (4 ). and for the Siemens ADVIA system (y ϭ 0.86x ϩ 0.64 g/dL. 95% CIs: slope, 0.76 -0.97; y intercept, 0.21-1.07 g/dL). For magnesium, 4 systems compared well [difference range, Ϫ1.5% (Roche COBAS) to 2.4% (Siemens ADVIA)], whereas the Abbott ARCHITECT test showed a difference of 11.2% (bias limit from biology, 1.8%). Note that the Roche COBAS difference is dependent on the magnesium concentration, amounting to Ϫ2.5% at 2.20 mg/dL [y ϭ 0.93x ϩ 0.10 mg/dL (0.041 mmol/L). 95% CIs: slope, 0.90 -0.97; y intercept, 0.04 -0.16 mg/dL (0.014 -0.067 mmol/L)]. Although the systems generally had good run-to-run performance (median CV, 1.2%), the study findings suggest some additional concerns. The dispersion of the residuals around the Mean overall was considerably higher for the Abbott ARCHITECT magnesium test than for the others (r ϭ 0.953; others, r Ͼ 0.995). The Siemens ADVIA peer group for magnesium showed relatively high imprecision (CV, 3.3%; CVs for the others, Ͻ1.6%). The differences for the replicate outliers obtained in the calcium tests (Ͼ6%) were considerably higher than the biological total error limit of 2.4%. This difference may provide incentive for further optimization of calcium tests in general. A limitation of the study was that the target values were not determined by reference measurement procedures, but such information would have had no effect on the differences between methods, which were our primary focus. In view of our results, we emphasize the need for restandardizing the Abbott ARCHITECT magnesium test and all of the albumin tests.
In summary, this study revealed excellent comparability of the totalprotein measurements. For calcium, the study demonstrated the need for tighter control of lot variation and suggested the need to further optimize this test. The results of this study reveal that the magnesium test for the Abbott ARCHITECT system requires improved quality and restandardization; the results also reiterate an urgent need for standardization of albumin tests (5 ). In conclusion, EQA surveys with single-donation samples, peer group formation according to test system, and Mean overall values for targets can serve as valuable benchmarks for the assessment of system quality and comparability, and they can provide valuable incentives for improvement. Problems with standardization have to be resolved by comparison with reference measurement procedures, be it on an international scale (albumin) or on the scale of the individual manufacturer (magnesium). Clinical Implications of a Recent Adjustment to the HighSensitivity Cardiac Troponin T Assay: User Beware
To the Editor:
Roche Diagnostics recently issued a technical bulletin calling for an adjustment to the calibration curve for the Elecsys Troponin T hs and Elecsys Troponin T hs STAT assays. Although this bulletin was disseminated widely in some countries, it was less widely distributed in others. The Roche highsensitivity (hs) assays are in clinical use worldwide except within the US, where they are used for research but have not yet been cleared by the Food and Drug Administration. Roche has characterized this action as a "minor adjustment" to the lowend standardization of the Troponin T hs assays in order to return to the original assay specifications. The new revised lots (numbers 167345 and 167650) yield measurable cardiac troponin T concentrations in hs assays in a greater proportion of patient samples for which the concentrations were undetectable with previous lots [163704 (Troponin T hs) and 164773 (Troponin T hs STAT)] and older lots (6 lots total). Specifically, Roche has indicated that the new lots will produce higher recoveries at low concentrations (3-20 ng/L) and produce a shift upward-as much as ϩ7 ng/L at concentrations of 3-8 ng/L and up to ϩ5 ng/L at concentrations of 8 -20 ng/L. Unfortunately, no correlation studies that compare earlier lots against the new lots are available. Thus, no information is available regarding what shifts may have occurred above the 20-ng/L value.
The implications of this calibration reformulation and the questions it raises are many. First, what will be the effect of the reformulation on the well-established 99th percentile value of 14 ng/L that has consistently been reported in the literature? Second, what percentage increase in detectable results will be seen among patients presenting for emergency care? Third, how does this change affect findings from the hundreds of published studies that have used both the 99th percentile value and ␦ changes over time to examine diagnostic accuracy, and how does it change the findings for risk stratification of acute coronary syndrome patients and apparently healthy patients? Fourth, what mechanisms are in place to alleviate customers' concerns that similar product adjustments for this hs assay that have substantial downstream implications for patient triage and management will not occur in the future? Fifth, does the new reformulated calibration curve permit recalculation of the concentrations that have already been published in the current literature? The answers to these questions are essential for customers trying to interpret the relationship of previous data to new data.
The occurrence of this problem is not surprising, considering the challenges presented by the quality assurance of hs assays. We have been perplexed by the fact that early data suggested that most healthy individuals have detectable values. In the PEACE (Prevention of Events with Angiotensin Converting Enzyme Inhibition) study (1 ), 97.7% of participants had a value above the limit of detection, which was 1 pg/mL (1 ng/L) at the time with a precommercial assay. In the original validation by Giannitsis et al. (2 ) , 80% of putatively healthy participants had values above the limit of the blank. By the time of the large international cooperative study, however, only 57% of putative healthy study participants had values above the limit of the blank, and only 32% had values above the limit of detection (3 ) . This percentage fell even further, with only 25% above this limit in a community-based study (4 ) . In addition, the original diagnostic study (1 ) found that the hs assay for cardiac troponin T did not detect more myocardial infarctions than conventional assays (5 ). Was this decrease due to the change now reported by Roche, or did some other change occur very early in the assay?
We believe that these findings have major implications for patient
